| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 251,359 | 55,067 | ||
| Short-term investments | 261,667 | 205,380 | ||
| Restricted cash | 105 | 105 | ||
| Prepaid expenses and other current assets | 7,528 | 9,690 | ||
| Total current assets | 520,659 | 270,242 | ||
| Total property and equipment | 4,834 | - | ||
| Less accumulated depreciation | 1,718 | - | ||
| Property and equipment, net | 3,116 | 3,172 | ||
| Operating lease right of use asset, net | 10,480 | 11,047 | ||
| Other assets | 1,068 | 1,034 | ||
| Total assets | 535,323 | 285,495 | ||
| Accounts payable | 3,235 | 3,176 | ||
| Accrued expenses and other current liabilities | 8,599 | 6,944 | ||
| Operating lease liability | 2,482 | 1,759 | ||
| Total current liabilities | 14,316 | 11,879 | ||
| Operating lease liability, net of current portion | 9,390 | 10,104 | ||
| Total liabilities | 23,706 | 21,983 | ||
| Common stock, 0.001 par value 500,000,000 shares authorized at september 30, 2025 and december 31, 2024 47,650,216 shares and 36,580,202 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 48 | 37 | ||
| Additional paid-in capital | 712,889 | 438,091 | ||
| Accumulated other comprehensive income | 145 | -76 | ||
| Accumulated deficit | -201,465 | -174,540 | ||
| Total stockholders' equity | 511,617 | 263,512 | ||
| Total liabilities and stockholders' equity | 535,323 | 285,495 | ||
Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics, Inc. (RAPP)